We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Mylan subsidiary has received the first World Health Organization (WHO) approval for a generic version of Abbott Laboratories’ Kaletra, an HIV protease inhibitor designed for distribution in warm climates.